Chien-Hung Chen
Overview
Explore the profile of Chien-Hung Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
432
Citations
5428
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kuo Y, Chen Y, Tsai M, Lu S, Hu T, Hung C, et al.
Am J Cancer Res
. 2025 Mar;
15(2):811-823.
PMID: 40084378
Atezolizumab plus bevacizumab (Ate/Bev) and lenvatinib (Len) are first-line therapies for unresectable hepatocellular carcinoma (uHCC). However, Ate/Bev's high cost limits its common use in real-life practice, while Len is usually...
2.
Wang H, Zeng Y, Huang C, Chen C, Kuo H, Tseng K, et al.
J Formos Med Assoc
. 2025 Mar;
PMID: 40023754
Purpose: This study investigated whether Fibrosis-4 (FIB-4) score and its change can serve as predictors of hepatocellular carcinoma (HCC) development in patients with chronic hepatitis C (CHC) infection receiving direct-acting...
3.
Chen C, Tai W, Hu T, Wang J, Hung C, Lu S
Am J Gastroenterol
. 2025 Feb;
PMID: 39996613
Objectives: This study investigated the patterns of HBV viremia change and HBsAg loss rate without retreatment within 2 years after nucleos(t)ide analogues (NA) cessation. Methods: We enrolled 481 patients who...
4.
Hsu Y, Wu M, Weng M, Lee Y, Chou H, Lee H, et al.
J Immunother Cancer
. 2025 Feb;
13(2).
PMID: 39979070
Background: Immunogenic cell death (ICD) can elicit an adaptive immune response with significant antitumor effects. Percutaneous ethanol injection therapy has been applied as tumor ablation for small hepatocellular carcinoma (HCC)....
5.
Chung S, Yong C, Kee K, Lu S, Hu T, Wang J, et al.
Langenbecks Arch Surg
. 2025 Feb;
410(1):66.
PMID: 39937293
Purpose: Few studies have compared survival outcomes between liver resection (LR) and percutaneous radiofrequency ablation (RFA) for treating solitary 3-5 cm hepatocellular carcinoma (HCC). We aimed to clarify this issue....
6.
Chen Y, Tsai P, Huang C, Chen C, Hung C, Chen C, et al.
J Formos Med Assoc
. 2025 Feb;
PMID: 39919992
Background/purpose: The risk of hepatocellular carcinoma (HCC) is increased in patients with chronic hepatitis C (CHC) and elevated alanine transaminase (ALT) levels. The association between HCC and ALT levels after...
7.
Lim Y, Yu M, Choi J, Chen C, Choi W, Kang W, et al.
Lancet Gastroenterol Hepatol
. 2025 Feb;
10(4):295-305.
PMID: 39914435
Background: Current guidelines for chronic hepatitis B recommend antiviral therapy for individuals with non-cirrhotic chronic hepatitis B only if they have significant liver fibrosis or elevated alanine aminotransferase (ALT) concentrations....
8.
Lee S, Yang S, Tsai P, Huang C, Chen C, Hung C, et al.
Clin Mol Hepatol
. 2025 Feb;
PMID: 39905837
Background & Aims: The survival benefit of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection in patients with hepatocellular carcinoma (HCC), particularly in BCLC stages B/C, remains largely...
9.
Fang H, Jeng W, Hu T, Wang J, Hung C, Lu S, et al.
Am J Gastroenterol
. 2025 Jan;
PMID: 39820130
Introduction: There is limited information comparing the off-therapy relapse rates of patients discontinued tenofovir alafenamide (TAF) to those stopping entecavir or tenofovir disoproxil fumarate (TDF). Methods: A total of 805...
10.
Dongelmans E, Hirode G, Hansen B, Chen C, Su T, Seto W, et al.
J Hepatol
. 2025 Jan;
82(3):446-455.
PMID: 39773379
Background & Aims: Flares after nucleos(t)ide analogue (NA) cessation are common and potentially harmful. Predictors of flares are required for risk stratification and to guide off-treatment follow-up. Method: This multicenter...